15.04

0.27% +0.04

After Hours: 15.04

Tourmaline Bio Inc (TRML)

Overview News Price History Financials Discussions Forecast

Tourmaline Bio Inc stock is currently priced at $15.04, with a 24-hour trading volume of 183.95K. It has seen a +0.27% increased in the last 24 hours and a -9.83% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $15.25 pivot point. If it approaches the $14.71 support level, significant changes may occur.

Previous Close:

$15.00

Open:

$15

24h Volume:

183.95K

Market Cap:

$385.72M

Revenue:

Net Income/Loss:

$11.77M

P/E Ratio:

-97.22

EPS:

-0.1547

Net Cash Flow:

$-19.23M

1W Performance:

+3.72%

1M Performance:

-9.83%

6M Performance:

-9.83%

1Y Performance:

+0.00%

1D Range:

$14.64

$15.45

52W Range:

$12.06

$48.31

Tourmaline Bio Inc Stock (TRML) Company Profile

Name

Tourmaline Bio Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

Address

27 West 24th Street, Suite 702, New York

Employee

Twitter

Next Earnings Date

2024-06-05

Latest SEC Filings

TRML's Discussions on Twitter

Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-15-23	Initiated	Jefferies	Buy
Dec-04-23	Resumed	H.C. Wainwright	Buy
Nov-17-23	Initiated	Truist	Buy
Oct-31-23	Initiated	Guggenheim	Buy
Oct-25-23	Initiated	Piper Sandler	Overweight
Oct-20-22	Initiated	H.C. Wainwright	Buy
Jul-05-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight

View All

Tourmaline Bio Inc Stock (TRML) Latest News

Tourmaline Bio, Inc. to Post Q2 2024 Earnings of ($0.70) Per Share, HC Wainwright Forecasts (NASDAQ:TRML) - MarketBeat

MarketBeat

Tourmaline Bio begins phase 2 trial of heart disease drug - Investing.com

Investing.com

Tourmaline Bio, Inc. to Post Q2 2024 Earnings of ($0.57) Per Share, Leerink Partnrs Forecasts (NASDAQ:TRML) - Defense World

Defense World

HC Wainwright Analysts Cut Earnings Estimates for Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

Defense World

Africa Energy (CVE:AFE) Share Price Crosses Above 50 Day Moving Average of $0.08 - Defense World

Defense World

HC Wainwright Reaffirms Buy Rating for Tourmaline Bio (NASDAQ:TRML) - Defense World

Defense World

Tourmaline Bio Inc Stock (TRML) Financials Data

Tourmaline Bio Inc (TRML) Net Income 2024

TRML net income (TTM) was $11.77 million for the quarter ending December 31, 2023.

Tourmaline Bio Inc (TRML) Cash Flow 2024

TRML recorded a free cash flow (TTM) of -$19.23 million for the quarter ending June 30, 2023.

Tourmaline Bio Inc (TRML) Earnings per Share 2024

TRML earnings per share (TTM) was $0.5785 for the quarter ending December 31, 2023.

Tourmaline Bio Inc Stock (TRML) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Kulkarni Sandeep Chidambar	CEO	Nov 17 '23	Buy	16.99	4,000	67,960	729,735
Thiara Parvinder	Director	Nov 17 '23	Buy	17.31	1,000	17,310	83,782
Castelein Caley	Director	Oct 27 '23	Buy	14.55	15,800	229,890	516,519
Kulkarni Sandeep Chidambar	CEO	Oct 26 '23	Buy	12.25	5,000	61,250	725,735
Castelein Caley	Director	Oct 25 '23	Buy	12.07	4,200	50,694	500,719
Thiara Parvinder	Director	Oct 25 '23	Buy	12.12	2,000	24,240	82,782
KANTOFF AARON	Director	Oct 24 '23	Buy	11.86	7,500	88,950	45,391
Thiara Parvinder	Director	Oct 24 '23	Buy	10.66	5,000	53,300	80,782
Kulkarni Sandeep Chidambar	CEO	Oct 24 '23	Buy	10.68	4,650	49,662	720,735
Ildstad Suzanne	Director	Jun 14 '23	Sale	2.49	12,942	32,244	3,771,392

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.